首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1379615篇
  免费   99193篇
  国内免费   2260篇
耳鼻咽喉   19607篇
儿科学   45529篇
妇产科学   40722篇
基础医学   200910篇
口腔科学   37999篇
临床医学   118184篇
内科学   273524篇
皮肤病学   29232篇
神经病学   107998篇
特种医学   52059篇
外国民族医学   367篇
外科学   208961篇
综合类   27217篇
现状与发展   1篇
一般理论   377篇
预防医学   105029篇
眼科学   31244篇
药学   105150篇
  1篇
中国医学   2766篇
肿瘤学   74191篇
  2018年   15097篇
  2017年   10928篇
  2016年   12048篇
  2015年   13976篇
  2014年   18862篇
  2013年   28902篇
  2012年   40700篇
  2011年   43350篇
  2010年   25085篇
  2009年   23038篇
  2008年   41291篇
  2007年   44456篇
  2006年   44895篇
  2005年   44069篇
  2004年   42224篇
  2003年   40864篇
  2002年   40136篇
  2001年   60292篇
  2000年   61911篇
  1999年   52686篇
  1998年   14958篇
  1997年   13384篇
  1996年   13617篇
  1995年   12778篇
  1994年   12131篇
  1993年   11200篇
  1992年   41969篇
  1991年   41199篇
  1990年   40704篇
  1989年   39469篇
  1988年   36774篇
  1987年   36026篇
  1986年   34348篇
  1985年   32743篇
  1984年   24448篇
  1983年   21254篇
  1982年   12715篇
  1981年   11218篇
  1979年   23142篇
  1978年   16195篇
  1977年   14012篇
  1976年   13257篇
  1975年   14501篇
  1974年   17103篇
  1973年   16462篇
  1972年   15657篇
  1971年   14524篇
  1970年   13567篇
  1969年   13055篇
  1968年   12281篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Molnár  B.  Aroca  S.  Dobos  A.  Orbán  K.  Szabó  J.  Windisch  P.  Stähli  A.  Sculean  A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with...  相似文献   
2.
3.
4.
5.
6.
7.
Vaccination is a vital health care initiative to prevent individual and population infection. To increase vaccination rates the federal government implemented the ‘No Jab, No Pay’ policy, where eligibility for several government benefits required children to be fully vaccinated by removing ‘conscientious objections’ and expanding the age range of children whose families receive benefits. This study assesses the impact of this policy at a local area within a single medical practice community in NSW, Australia. A retrospective clinical audit was performed between 2012 and 2017 on a single general practice's vaccination records for children ≤19 years. Catch-up vaccinations were assessed based on age at vaccination. Incidence of catch-up vaccinations was assessed for each of four years before and two years after the implementation of the ‘No Jab, No Pay’ policy in January 2016, along with the age of children and vaccination(s) given. Catch-up vaccinations were assessed temporally either side of implementation of ‘No Jab, No Pay’. Comparing the average annual vaccination catch-up incidence rate of 6.2% pre-implementation (2012–2015), there was an increase to 9.2% in 2016 (p < .001) and 7.8% in 2017 (p = .027). Secondary outcome measurement of catch-up vaccination incidence rates before (2012–2015) and after (2016–2017) ‘No Jab, No Pay’ implementation showed statistically significant increases for children aged 8–11 years (3.2%–5.6%, p = .038), 12–15 years (7.5%–14.7%, p < .001) and 16–19 years (3.3%–10.2%, p < .001) along with a statistically significant reduction in children aged 1–3 years (11.4%–6.2%, p = .015). Also, catch-up rates for DTPa significantly increased after program implementation. This study demonstrates that the Australian federal government vaccination policy ‘No Jab, No Pay’ was coincident with an increase in catch-up vaccinations within a rural NSW community served by one medical practice, especially for older children.  相似文献   
8.
Introduction: The landscape of poly (ADP-ribose) polymerase (PARP) inhibition in ovarian cancer is rapidly evolving and becoming increasingly complex. Ovarian cancer is leading therapeutic innovation by providing the proof of concept for DNA repair as a target. Three different PARP inhibitors have now received approvals in the US and Europe in different indications. Subtle but crucial differences can be found among the licensed indications for each PARP inhibitor in terms of histology, type of BRCA mutation (germline and/or somatic), number of prior lines of chemotherapy and whether the indication is in the treatment or maintenance settings.

Areas covered: We review the latest clinical data regarding the PARP inhibitor rucaparib in ovarian cancer, provide an update on the evolving landscape of PARP inhibition in ovarian cancer, and summarize avenues of ongoing and future research.

Expert opinion: All eligible patients should be offered a PARP inhibitor. SOLO1 trial results demonstrated an unprecedented benefit maintenance with PARP inhibitors in first line. Results from trials evaluating PARP inhibitors as maintenance in first line regardless of BRCA status and from trials evaluating combinatorial strategies are eagerly awaited.  相似文献   

9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号